On July 3, Insilico Medicine fell 6.32% in regular trading, trading at HKD 35.1/share, with turnover of HKD 505 million. The decline reflects continued selling pressure following the company's announcement of a strategic partnership with Takeda Pharmaceutical worth up to $600 million.

On July 2, the company disclosed the global collaboration leveraging its Pharma.AI platform to advance drug candidates across multiple therapeutic areas for Takeda. Under the deal, Insilico will receive approximately $60 million in project initiation and near-term milestone payments, with total potential value reaching $600 million including development, regulatory, and commercial milestones plus tiered royalties. However, the stock opened up over 10% on the news before reversing to close down 4.09%, triggering a classic buy-the-news selloff pattern that has extended into today.

Adding to the pressure, the stock experienced an 11.12% drop on June 30 when a major lock-up expiry released significant shares into the market. Fundamentally, the company reported a 34.48% YoY revenue decline and a net loss of $352 million, with market participants questioning whether large BD deal signings can translate into near-term revenue.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)